In the past W. Carpenter has collaborated on articles with J. Smith. One of their most recent publications is The identification of some of the oxidation products of tetrakis(dimethylamino)ethylene. Which was published in journal Tetrahedron.

More information about W. Carpenter research including statistics on their citations can be found on their Copernicus Academic profile page.

W. Carpenter's Articles: (2)

The identification of some of the oxidation products of tetrakis(dimethylamino)ethylene

AbstractBy use of mass spectrometry seven additional compounds have been identified from the autoxidation products of tetrakis(dimethylamino)ethylene. These are trimethylformamidine, dimethylformamide, methylformamide, trimethylurea, 2-dimethylamino-N,N′-dimethylacetamidine, hexamethyloxamidine, and 2-dimethylamino-2-oxo-trimethylacetamidine. Their origin is discussed in terms of known chemistry of tetrakis(dimethylamino)ethylene and its derivatives.

715Use of dd-cfDNA in Real World Practice: Single Center Experience

PurposeGene expression profiling testing (GEP; AlloMap) and donor-derived cell free DNA (dd-cfDNA; AlloSure) each provide non-invasive means to detect possible heart allograft rejection, including acute cellular rejection (ACR). This report describes the largest single center use of dd-cfDNA to date.MethodsPost heart transplant (HT) management is standardized at our center such that endomyocardial biopsy is used for rejection surveillance in the early period with crossover to GEP testing at day 56. Elevated GEP (≥34) prompts biopsy. dd-cfDNA was utilized in conjunction with biopsy or in lieu of biopsy (barrier to biopsy). A cohort of 26 HT patients underwent dd-cfDNA testing, including 3 multiorgan (same donor) and 5 retransplant patients. The dd-cfDNA (%, AlloSure) and GEP (AlloMap, score 0-40) results were correlated patient survival.ResultsAmong 26 HT patients there was a total 70 dd-cfDNA tests (mean 2.7 per pt). dd-cfDNA usage was due to inability to biopsy (33%), anticoagulation (22%), elevated GEP (26%), with graft dysfunction, prior rejection, biopsy refusal, tricuspid regurgitation and critically ill status comprising 4% each. Mean day post HT for first dd-cfDNA test was 201 (IQR 90-517), with earliest at day 7 post HT. Mean dd-cfDNA was 0.3 ± 0.5%. Mean GEP score was 32.8 ± 5.3. There were no deaths in this cohort. One patient had confirmed AMR2 (dd-cfDNA 0.25%). Mean LVEF 54% ± 5.ConclusionIn surveillance of heart allograft recipients for rejection, consideration of dd-cfDNA levels may improve patient management decisions particularly when endomyocardial biopsy may not be feasible.

Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!

Contact us